Conexeu Sciences targets a $1 Billion opportunity in tissue restoration as weight-loss drugs increase demand for facial and body volume treatments.
Conexeu Sciences Inc. (Nasdaq: CNXU) CEO Miles Harrison outlined the company’s strategy to address tissue regeneration needs driven by widespread GLP-1 weight-loss drug use. Demand for treatments restoring lost facial and body volume is rising, creating a market current fillers and injectables do not fully serve.
The preclinical-stage company focuses on a single bioregenerative extracellular matrix (ECM) platform, CXU, designed to scale across wound care, aesthetics, oral health, and veterinary medicine. Key catalysts include an upcoming FDA 510(k) submission and progress in its breast implant alternative program.
Harrison emphasized the platform’s potential to replace silicone implants with a bioresorbable regenerative scaffold, targeting multiple medical applications with one core technology.